---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-078428"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T08:36:20.999686+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PepGen discontinues DMD program after PGN-EDO51 misses dystrophin target; shifts focus to DM1

## Summary
- 10 mg/kg PGN-EDO51: total dystrophin only 0.59% of normal (mean increase 0.36%); exon skipping +3.5%.
- Company voluntarily discontinuing PGN-EDO51 and winding down all DMD research & development.
- DM1 program prioritized; FREEDOM-DM1 15 mg/kg data expected H2 2025, FREEDOM2-DM1 5 mg/kg data Q1 2026.
- PGN-EDO51 safety favorable; all treatment-related AEs mild, no serious adverse events.
- Prior DM1 data (10 mg/kg single dose) showed 29% mean mis-splicing correction at safety update.

## SEC filing metadata
- accession: 0000950170-25-078428
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017025078428/0000950170-25-078428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017025078428/pepg-20250528.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-078428
- JSON: https://secwatch.observer/filing/0000950170-25-078428.json
- Plain text: https://secwatch.observer/filing/0000950170-25-078428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.